X

Trial Profile

A Multi-center Phase Ib/II Trial of Nivolumab/Ipilimumab-Primed Immunotransplant for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Diffuse large B cell lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

04 Apr 2022 Status changed from recruiting to completed.
08 Jun 2021 Results (n=6) assessing safety and efficacy of nivolumab / ipilimumab primed immunotransplant in post-CAR-T and post-ASCT diffuse large b cell lymphoma, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
16 Dec 2019 Planned End Date changed from 27 Nov 2019 to 27 Nov 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com